Evidence map›Paper›PMID 41552190›Full record

ArticleCureus2025

Dasatinib-Associated Recurrent Symptomatic Bilateral Pleural Effusions in an Elderly Patient With End-Stage Renal Disease on Maintenance Hemodialysis.

Macaulay A Onuigbo, Margaret Butler, Jessica Biediger

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Macaulay A OnuigboMedicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, USA.
Margaret ButlerMedicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, USA.
Jessica BiedigerMedicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dasatinib, a second-generation tyrosine kinase inhibitor, is effective in treating chronic myeloid leukemia but can occasionally cause pleural effusions, even after long-term therapy. We present the case of an 87-year-old male with end-stage renal disease (ESRD) on thrice-weekly maintenance hemodialysis who, over eight months in 2025, required repeated bilateral therapeutic thoracenteses for recurrent symptomatic pleural effusions. These effusions developed more than seven years after initiating dasatinib, raising the question of whether they were secondary to dasatinib, ESRD-associated hypervolemia, or newly diagnosed pulmonary hypertension.

Indexed as

bilateral pleural effusionschronic myeloid leukemia (cml)dasatinibintradialytic parenteral nutritionmaintenance hemodialysis

Identifiers

PMID41552190
PMCPMC12812047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.